Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13938473 | 0.80 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL5201218 | 0.80 | SMYD3 (0.44) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL7875062 | 0.79 | — | — | |
| SCHEMBL10045647 | 0.77 | LMNA (0.44) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL27040299 | 0.71 | LMNA (0.40) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL13779949 | 0.69 | ALDH1A1 (0.59) | NPC1RAB9AMAPTALDH1A1GFER | |
| SCHEMBL338764 | 0.68 | SMN1; SMN2 (0.39) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL27040200 | 0.68 | SMN1; SMN2 (0.39) | NPC1RAB9ASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL5865621 | 0.67 | — | — | |
| SCHEMBL6503803 | 0.66 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTLMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912666-B2 | Synthesis of 6-oxo-1,4,5,6-tetrahydropyridizin-3-carboxylic acid | MILLENNIUM ENTPR INC (US) | 2024-02-27 | — | — | US | claimed |
| US-11800869-B2 | Use of 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid, 1-methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid and 1-alkyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid for improving growth performance in plants | Advanced Crop Chem LLP (US) | 2023-10-31 | — | — | US | claimed |
| US-20220372002-A1 | SYNTHESIS OF 6-OXO-1,4,5,6-TETRAHYDROPYRIDIZIN-3-CARBOXYLIC ACID | Millennium Enterprises, Inc. (US) | 2022-11-24 | — | — | US | claimed |
| EP-1814880-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INT (ES) | 2009-01-28 | — | — | EP | claimed |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| US-6946462-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | claimed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SALARIUS PHARMACEUTICALS INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250302838-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX LLC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4554674-A1 | BIARYL ETHER UREA COMPOUNDS AS FAAH INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-05-21 | — | — | EP | disclosed |
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| US-5559232-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0641779-A1 | Novel 1-amidinopiperdines and 4-amidinomorpholines as aggregation inhibitions | F. HOFFMANN-LA ROCHE AG (CH) | 1995-03-08 | — | — | EP | disclosed |
| US-5229386-A | Anticoagulants, hypotensive agents, antiallergens, antiinflammatory agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-20 | — | — | US | disclosed |
| US-5145860-A | Anticoagulants, vasodilators, antiinflammatory, antiallergens, enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-09-08 | — | — | US | disclosed |
| WO-1992002513-A1 | HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-20 | — | — | WO | disclosed |
| EP-0388909-A2 | Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | NPC1 71/4885RAB9A 2425/4885SMN1; SMN2 2811/4885 |
| US-20220372002-A1 | SYNTHESIS OF 6-OXO-1,4,5,6-TETRAHYDROPYRIDIZIN-3-CARBOXYLIC ACID | OGDH, PGD, HPD | NPC1 3824/4885RAB9A 4695/4885SMN1; SMN2 4045/4885 |
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LANCL2, CBS, LCP2 | NPC1 1564/4885RAB9A 2591/4885SMN1; SMN2 3536/4885 |
| US-20250302838-A1 | 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | AQP3, AQP4, AQP1 | NPC1 571/4885RAB9A 2873/4885SMN1; SMN2 1263/4885 |
| US-20250382240-A1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, TLR5, IDO1 | NPC1 2138/4885RAB9A 2388/4885SMN1; SMN2 1721/4885 |
| US-20080200473-A1 | Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto | GABRA1, GABRA2, GABRA3 | NPC1 807/4885RAB9A 1380/4885SMN1; SMN2 1951/4885 |
| US-11912666-B2 | Synthesis of 6-oxo-1,4,5,6-tetrahydropyridizin-3-carboxylic acid | OGDH, PGD, HPD | NPC1 3824/4885RAB9A 4695/4885SMN1; SMN2 4045/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | NPC1 71/4885RAB9A 2425/4885SMN1; SMN2 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.